Posted by Michael Wonder on 28 Feb 2023
Schedule of Pharmaceutical Benefits - 1 March 2023
1 March 2023 - The March 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The March issue of the Schedule includes a few major new/revised listings:
- Adalimumab (Yuflyma) - new biosimilar medicine
- Ipilimumab (Yervoy) - restriction change
- Nivolumab (Opdivo) - restriction change
